Work

LBA43 NAPISTAR 1-01: A phase I dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC)

Year: 2025

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.09.055

Authors: A. González-Martín, J. Sehouli, E.I. Braicu, S. Sen, V. Boni, R.S. Kristeleit, I. Matos Garcia, S. Ochsenreither, D.L. Richardson, A.I. Spira, A. Starodub, J. Wolf, K. de Graaf, B. Hock, Y. Houvras, I.I. Monteiro Vasconcelos, G. Fingerle-Rowson, T. Van Gorp

Institutions: Clinica Universidad de Navarra, Charité – Universitätsmedizin Berlin, Guy's and St Thomas' NHS Foundation Trust, OU Health Stephenson Cancer Center, Christ Hospital, University Hospital Cologne, Tubulis (Germany), Universitair Ziekenhuis Leuven

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4416387685

Cites:

Cited by: 3

Related to: 10